--- title: "Indaptus Therapeutics names Tim Ruan and Yi Zhang as independent directors; Matthew McMurdo resigns" type: "News" locale: "en" url: "https://longbridge.com/en/news/283808882.md" description: "Indaptus Therapeutics has appointed Tim Ruan and Yi Zhang as independent directors, effective April 22, 2026, while Matthew McMurdo has resigned from the board on the same date. Ruan, a financial executive and CFO of Ocumension Therapeutics, will serve on the Audit Committee, while Zhang, an IP and life sciences expert, will join the Nominating Committee. McMurdo's resignation was not due to any disagreements with the company." datetime: "2026-04-23T10:13:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283808882.md) - [en](https://longbridge.com/en/news/283808882.md) - [zh-HK](https://longbridge.com/zh-HK/news/283808882.md) --- # Indaptus Therapeutics names Tim Ruan and Yi Zhang as independent directors; Matthew McMurdo resigns **Indaptus Therapeutics appointed Tim Ruan and Yi Zhang as independent directors effective April 22, 2026, and reported the resignation of director Matthew McMurdo effective April 22, 2026.** Individual Tim Ruan Yi Zhang (Johnny) Matthew McMurdo Role Independent Director; Audit Committee member; Audit committee financial expert Independent Director; Nominating Committee member Director Type of Change Appointed Appointed Resigned Effective Date April 22, 2026 April 22, 2026 April 22, 2026 Reason Not disclosed Not disclosed Resignation not due to any disagreement with the Company on operations, policies or practices Replacement Info Not disclosed Not disclosed Not disclosed Background Details 40-year-old financial executive; CFO of Ocumension Therapeutics; former Exec. Director at Goldman Sachs (Asia) and VP at Morgan Stanley Asia; MS in Biotechnology (HKUST); BCom (Finance) and LLB (UNSW) 48-year-old IP and life sciences expert; Partner at JunHe; registered U.S. patent attorney; Ph.D. in Molecular, Cellular & Developmental Biology (Iowa State); J.D. (Georgetown) Not disclosed Board/Committee Role Changes Appointed to Audit Committee; qualifies as audit committee financial expert Appointed to Nominating Committee Not disclosed Original SEC Filing: Indaptus Therapeutics, Inc. \[ INDP \] - 8-K - Apr. 22, 2026 **Disclaimer** This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. ### Related Stocks - [INDP.US](https://longbridge.com/en/quote/INDP.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) ## Related News & Research - [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md) - [](https://longbridge.com/en/news/286807703.md) - [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md) - [Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery](https://longbridge.com/en/news/287100303.md) - [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)